![Christine Cvijic](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 3 M $ al 31/05/2026
Christine Mikail Cvijic was the founder of Neumentum, Inc., founded in 2017, where the title held was Director.
Current jobs include President, Chief Financial Officer & Director at Neurogene, Inc. starting in 2026, and President & Chief Financial Officer at Neurogene, Inc. (New York) starting in 2019.
Former jobs include Independent Non-Executive Director at Advanced Accelerator Applications SA from 2017 to 2018; Senior Vice President-Corporate Development at Savient Pharmaceuticals, Inc. from 2011 to 2012; Secretary, Vice President & General Counsel at ImClone LLC in 2011; Secretary, SVP-Legal Affairs & General Counsel at NPS Pharmaceuticals, Inc. from 2014 to 2015; Secretary & Executive VP-Corporate Development at Dendreon Corp.; and Chief Administrative Officer & General Counsel at Sio Gene Therapies, Inc. from 2015 to 2017.
Education includes undergraduate studies at Rutgers State University of New Jersey and graduate studies at Fordham University School of Law.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0,6 % | 06/05/2026 | 93.640 ( 0,6 % ) | 3 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Operates as a clinical stage company that develops genetic medicines for neurological diseases | Director Financiero/CFO | 24/09/2019 |
| Empresas | Cargo | Fin |
|---|---|---|
| ADVANCED ACCELERATOR APPLICATION SA(ADR) | Director/Miembro de la Junta | 01/03/2018 |
| SIO GENE THERAPIES INC. | Director Administrativo | 01/03/2017 |
| NPS PHARMACEUTICALS, INC. | Consejero General | 01/02/2015 |
| SAVIENT PHARMACEUTICALS INC | Corporate Officer/Principal | 02/02/2012 |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Consejero General | 01/02/2011 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for bone and mineral disorders | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Advanced Accelerator Applications SA
 Advanced Accelerator Applications SA Pharmaceuticals: MajorHealth Technology Develops and produces nuclear medicine and radioligand therapies | Health Technology |
Fordham University School of Law
 Fordham University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Neumentum, Inc.
 Neumentum, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Operates as a clinical stage company that develops genetic medicines for neurological diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
